Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
DANVERS, Mass., Jan. 26, 2016 -- Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, February 4, 2016, the Company will release financial results for the third quarter of fiscal 2016. The Company will host a conference call to discuss the results on Thursday, February 4, 2016, at 8:00 a.m. EST. Michael R. Minogue, Chairman, President and Chief Executive Officer; Michael Tomsicek, Vice President and Chief Financial Officer, will host the conference call.
To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11 a.m. EST February 4, 2016 through 11:59 p.m. EST on February 6, 2016. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 3101592.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
For further information please contact: Ingrid Goldberg Director, Investor Relations 978-646-1590 [email protected]
